Answers are grounded in this paper and cite their sources.
Hypochondroplasia (HCH) is a fibroblast growth factor receptor 3 (FGFR3)-related skeletal dysplasia characterized by disproportionate short stature and altered body proportions. Beyond growth impairment, individuals with HCH frequently display abnormal body composition and increased adiposity, which may contribute to adverse cardiometabolic outcomes. Vosoritide, a C-type natriuretic peptide (CNP) analog that promotes endochondral bone growth by antagonizing FGFR3 signaling, is approved for achondroplasia and has recently shown efficacy in improving growth velocity in children with HCH.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: